RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines ...Middle East

PR Newswire - News
GAITHERSBURG, Md., March 29, 2022 /PRNewswire/ -- RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A...

Read More Details
Finally We wish PressBee provided you with enough information of ( RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines )

Apple Storegoogle play

Also on site :



Latest News